Revenue Performance - Q4 2025 revenue reached a record $6.0 million, growing 43% year-over-year and 13% sequentially[2] - Full year 2025 revenue was approximately $16.1 million, up from $10.7 million in 2024, with $9.7 million from recurring non-capital revenue[10] - Total revenue for the year ended December 31, 2025, was $16,098,000, representing a 50.5% increase from $10,680,000 in 2024[28] Gross Margin and Profitability - Gross margin for Q4 2025 was 67%, down from 71% in the prior year, primarily due to product mix and introductory pricing[7] - Full year 2025 gross margin improved to 71%, compared to 66% in the prior year, driven by increased selling prices and capital system sales[11] - Gross profit for the year ended December 31, 2025, was $11,393,000, up from $7,037,000 in 2024, indicating a gross margin improvement[28] Operating Expenses - Total operating expenses for Q4 2025 were approximately $11.4 million, slightly up from $11.3 million in the prior year[8] - Total operating expenses for the full year 2025 were approximately $52.6 million, up from $40.1 million in 2024, due to increased headcount and trial-related costs[12] - Operating expenses for the year increased to $52,647,000 in 2025 from $40,099,000 in 2024, primarily driven by higher research and development costs[28] Net Loss - The net loss for Q4 2025 was approximately $8.2 million, or $0.27 per share, compared to a net loss of $4.9 million, or $0.20 per share, in Q4 2024[9] - The net loss attributed to shareholders for the year was $42,570,000, compared to $27,816,000 in 2024, reflecting increased investment in growth initiatives[29] Cash and Assets - The company had cash of approximately $59.7 million as of December 31, 2025[14] - Cash and cash equivalents at the end of 2025 were $59,723,000, an increase from $54,912,000 at the end of 2024[30] - Total current assets rose to $76,089,000 in 2025, up from $69,065,000 in 2024, driven by increases in cash and inventory[26] Liabilities and Financing - Total liabilities increased to $11,041,000 in 2025 from $9,812,000 in 2024, with long-term debt rising to $4,499,000[27] - The company issued common shares worth $42,436,000 in 2025, compared to $62,106,000 in 2024, indicating a decrease in financing activities[31] Research and Development - Research and development expenses for the year were $20,596,000, up from $16,965,000 in 2024, reflecting ongoing investment in product development[28] Market and Product Outlook - The TULSA-PRO installed base increased to 78 systems, with expectations to reach approximately 120 installs by the end of 2026[2] - 67% of patients treated with TULSA-PRO in Q4 2025 were for prostate cancer only, with a diverse patient profile including hybrid and salvage cases[2] - The company anticipates continued growth in revenues from its TULSA-PRO and Sonalleve systems, although specific future revenue expectations were not disclosed[25]

Core Insights - Profound Medical Corp. reported a record revenue of $6.0 million for Q4 2025, reflecting a 43% year-over-year growth and a 13% sequential increase [2][5] - The company anticipates reaching approximately 120 TULSA-PRO installations by the end of 2026, up from 78 as of December 31, 2025, driven by a growing sales pipeline [2] - Profound's technologies, particularly the TULSA Procedure, are gaining traction in treating various prostate diseases, with a significant portion of patients treated for prostate cancer [2][21] Business Highlights - The TULSA-PRO qualified sales pipeline includes 110 new systems in various stages of the sales process [2] - In Q4 2025, 67% of patients treated were for prostate cancer, with a diverse range of cancer grades and treatment intentions [2] - The company launched the TULSA-AI Volume Reduction module, aimed at optimizing BPH treatment, which is expected to triple the total available market for prostate disease to about 600,000 patients annually [3][2] Financial Performance - For the full year 2025, Profound recorded total revenue of approximately $16.1 million, up from $10.7 million in 2024 [10] - The gross margin for Q4 2025 was 67%, down from 71% in the prior year, attributed to product mix and introductory pricing in new markets [6] - The net loss for Q4 2025 was approximately $8.2 million, compared to a net loss of $4.9 million in Q4 2024 [9] Operating Expenses - Total operating expenses for Q4 2025 were approximately $11.4 million, slightly up from $11.3 million in the prior year, primarily due to increased headcount and sales force [8] - For the full year 2025, operating expenses totaled approximately $52.6 million, compared to $40.1 million in 2024, driven by increased enrollment in clinical trials and higher material costs [12] Liquidity and Share Capital - As of December 31, 2025, Profound had cash reserves of approximately $59.7 million [14] - The company completed a $36.0 million registered direct offering and a $6.45 million private placement to strengthen its balance sheet [7] Leadership Changes - Frank Baylis has been appointed to the Board of Directors, succeeding Kris Shah, who resigned [14][18]

Core Insights - Profound Medical Corp. will announce its fourth quarter and full year 2025 financial results on March 5, 2026, followed by a conference call to discuss the results and business developments [1][2]. Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing innovative interventional MRI (iMRI) procedures [3]. Product Offerings - The company is commercializing TULSA-PRO, a technology that integrates real-time MRI, AI-enhanced planning, and robotically-driven ultrasound for treating prostate diseases. The TULSA Procedure is designed to preserve urinary continence and sexual function while effectively targeting prostate tissue [4]. - TULSA-PRO is CE marked, Health Canada approved, and has received 510(k) clearance from the U.S. FDA [4]. - Profound is also marketing Sonalleve, a therapeutic platform approved for treating uterine fibroids and other conditions. It has received CE marking and FDA approval under a Humanitarian Device Exemption for specific treatments [5].

Core Insights - Profound Medical Corp. has been awarded the 2025/2026 Mount Logan Award for its achievements in interventional MRI procedures, particularly for the TULSA Procedure [1][2] Company Achievements - The company has treated its 4,000th TULSA Procedure patient and secured new U.S. reimbursement codes from Medicare, enhancing its market position [2] - Profound Medical has established strategic partnerships to expand global patient access to its technologies [2] - The TULSA Procedure is a significant advancement in prostate care, utilizing robotically controlled ultrasound and real-time MRI thermography for precise treatment [2][5] Technology Overview - The TULSA Procedure employs a unique method of delivering ultrasound from within the urethra to heat prostate tissue to 'kill temperature' (55-57°C), minimizing side effects and ensuring no procedural blood loss [2][5] - The procedure is incision-free, requires no overnight hospital stay, and allows for a quick recovery, making it a compelling option for patients [5] Market Position and Future Plans - Currently, there is only one TULSA-PRO system installed in Canada, but the company aims to increase installations following the regain of exclusive distribution rights in the country [3] - Profound Medical is deploying a direct sales team in North America and partnering with strategic distribution partners to enhance its global reach [3] Additional Products - Profound Medical is also commercializing Sonalleve, a therapeutic platform approved for treating uterine fibroids and other conditions, with potential applications in non-invasive cancer treatments [6]

Core Insights - Profound Medical Corp. has achieved a significant milestone with the completion of its 500th Sonalleve Procedure at PRO FAMILIA Specialist Hospital in Poland, reflecting the growing adoption of non-surgical treatment options for uterine conditions [1][2] - The Sonalleve technology offers a non-invasive alternative for treating uterine fibroids and adenomyosis, providing targeted relief without incisions, blood loss, or the need for overnight hospital stays [1][2] - The company is also focused on the commercialization of TULSA-PRO, which is designed for prostate disease treatment, emphasizing its unique ability to minimize side effects associated with traditional surgical methods [3][5] Company Overview - Profound Medical Corp. is a commercial-stage medical device company that specializes in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [4] - The company is actively commercializing two main products: TULSA-PRO for prostate conditions and Sonalleve for gynecologic disorders, both of which utilize advanced imaging and therapeutic technologies [5][7] Product Details - Sonalleve has been operational in Europe, China, and Southeast Asia, with over 4,000 women treated for uterine conditions, demonstrating effective pain and symptom relief while preserving fertility [2][3] - TULSA-PRO employs real-time MRI guidance and is designed to treat a wide range of prostate diseases, ensuring preservation of urinary continence and sexual function [5][6] - Both Sonalleve and TULSA-PRO have received various regulatory approvals, including CE marking and FDA clearance, indicating their compliance with safety and efficacy standards [6][7]

Core Insights - Profound Medical Corp. is a commercial-stage medical device company focused on AI-powered, MRI-guided, incision-free therapies for ablation of diseased tissue [1][3] Company Overview - Profound Medical is known for its TULSA-PRO technology, which integrates real-time MRI, AI-enhanced planning, and robotic ultrasound for prostate disease treatment [4] - The TULSA Procedure is designed to treat various prostate conditions, including low-, intermediate-, and high-risk prostate cancer, benign prostatic hyperplasia (BPH), and salvage therapy for radio-recurrent localized prostate cancer [4] - The procedure is incision-free, radiation-free, and typically completed in a single session, with patients experiencing quick recovery [4] - TULSA-PRO has received CE marking, Health Canada approval, and 510(k) clearance from the FDA [4] Additional Products - Profound Medical is also commercializing Sonalleve, a platform approved for treating uterine fibroids, adenomyosis, and pain from bone metastases, among other conditions [5] - Sonalleve has received CE marking and FDA approval under a Humanitarian Device Exemption for specific treatments and is being explored for additional applications in cancer therapy [5] Upcoming Events - The company will participate in the Lake Street Life-Sciences Invitational on February 4-5 in Scottsdale, AZ, and the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10-11 in Snowbird, UT [6]

Company Overview - Profound Medical (PROF) shares increased by 9.5% to close at $8.34, with trading volume significantly higher than usual, contrasting with a 0.3% loss over the past four weeks [1] - The rise in share price followed the successful treatment of a prostate cancer patient at Mount Sinai Hospital using the TULSA-PRO system, which integrates advanced technologies for treatment [2] Financial Performance - The company is projected to report a quarterly loss of $0.28 per share, reflecting a year-over-year decline of 40%, while revenues are expected to reach $8 million, marking a 91.4% increase from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Profound Medical operates within the Zacks Medical - Drugs industry, where Rigel Pharmaceuticals (RIGL) also holds a Zacks Rank of 3 (Hold) and has seen a 3.4% decrease in its share price [4][5] - Rigel's consensus EPS estimate for its upcoming report is $1.17, representing a 46.3% increase from the previous year, with its stock also experiencing a decline of 6.7% over the past month [5]

Core Insights - Mount Sinai Hospital has successfully treated its first prostate cancer patient using the TULSA-PRO system, marking a significant advancement in prostate care with AI-powered, MRI-guided therapy [1][4] Group 1: TULSA Procedure Overview - The TULSA Procedure™ utilizes robotically controlled directional ultrasound to heat prostate tissue to 'kill temperature' (55-57°C), while protecting surrounding nerves, resulting in no procedural blood loss and a quicker recovery [2][9] - This procedure is designed to treat a range of prostate diseases, including prostate cancer and benign prostatic hyperplasia (BPH), with minimal side effects such as urinary incontinence and erectile dysfunction [2][8] Group 2: Collaboration and Leadership - Mount Sinai is the first health system in the New York Metro Area to offer the TULSA Procedure, establishing itself as a leader in robotic surgical care [4] - The collaboration between the Department of Urology and the Department of Interventional Radiology at Mount Sinai aims to pave the way for future studies and guidelines in prostate cancer and BPH treatment using TULSA-PRO [5] Group 3: Technology and Market Potential - TULSA-PRO combines real-time MRI, AI-enhanced planning, and temperature feedback control, positioning it as a potential mainstream treatment for various prostate conditions [8] - The procedure is CE marked, Health Canada approved, and 510(k) cleared by the U.S. FDA, indicating its regulatory compliance and market readiness [9]

Core Insights - Profound Medical Corp. has successfully increased its TULSA-PRO installed base to 78 systems by the end of 2025, surpassing its target of 75 installations [1] - The qualified sales pipeline for TULSA-PRO has expanded to 97 new systems, indicating strong market interest and potential for future sales [2] - The CEO of Profound Medical anticipates that the growing installed base will lead to higher patient treatment rates and an increase in high-margin recurring revenue, driven by the TULSA Procedure's effectiveness in treating a wide range of prostate diseases while preserving patient functions [3] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [4] - The TULSA-PRO system utilizes advanced technology, including real-time MRI, AI-enhanced planning, and temperature feedback control, to provide precise treatment for various prostate conditions [5] - Profound is also commercializing Sonalleve, a therapeutic platform approved for treating uterine fibroids and other conditions, and is exploring additional treatment markets for this technology [6]

Core Insights - Profound Medical Corp. has achieved a significant milestone with the launch of its TULSA-PRO system at The Johns Hopkins Hospital, marking the beginning of non-clinical-trial treatments for prostate cancer using this advanced technology [1][3] Company Overview - Profound Medical is a commercial-stage medical device company focused on developing and marketing AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [4] Technology and Procedure - The TULSA Procedure™ utilizes robotically controlled directional ultrasound to treat prostate cancer and benign prostatic hyperplasia (BPH) by heating prostate tissue to 'kill temperature' (55-57°C) while preserving surrounding nerves [2][5] - Real-time MRI thermography allows for continuous visualization and temperature adjustments during the procedure, resulting in no procedural blood loss, no overnight hospital stay, and a quicker recovery for patients [2][5] Clinical Development and Approval - Johns Hopkins University played a crucial role in the clinical development of TULSA-PRO, participating in pivotal clinical trials that led to FDA clearance and further studies to validate its efficacy [3] - TULSA-PRO is CE marked, Health Canada approved, and has received 510(k) clearance from the U.S. FDA, indicating its regulatory compliance and readiness for commercialization [5] Market Potential - The TULSA Procedure has the potential to become a mainstream treatment for a wide range of prostate conditions, including low-, intermediate-, and high-risk prostate cancer, as well as BPH and salvage therapy for radio-recurrent localized prostate cancer [5]